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Cross-talk between primary 
osteocytes and bone 
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Shujun Wang4, Keolebogile Shirley Caroline Mamotswere Motaung  5, Ruihua Guo1, 
Chunxiao Wang1, Jeyashakila Robinson6, Joe M. Regenstein7, Bin Bao1 & Wenhui Wu1,4
Homeostasis of osteoclast formation from bone marrow macrophages (BMM) is regulated by paracrine 
signals of the neighbourhood bone cells particularly mesenchymal stem cells (MSC), osteoblasts and 
osteocytes (OC). Besides paracrine cues, collagen and glycosaminoglycan are involved in controlling 
bone homeostasis. Towards this approach, different molecular weight collagens were reacted with 
MSC, OC and BMM to understand the bone homeostasis activity of collagen. The up-regulating effect 
of collagens on osteogenic cell growth was confirmed by the presence of mineralized nodules in the 
osteoblastogenic lineage cells and increased osteogenic stimulatory gene expression. The decreased 
BMM-derived TRAP+ osteoclasts number and osteoclastogenic regulatory gene expression of OC could 
demonstrate the exploitive osteoclastogenic activity of collagens. Osteoclastogenesis from BMM was 
triggered by paracrine cues of OC in some extend, but it was down-regulated by collagen. Overall, the 
effect of collagen on osteoclastogenesis and osteoblastogenesis may depend on the molecular weight 
of collagens, and collagen suppresses osteoclastogenesis, at least in part by downregulating the 
secretion of cytokines in OC.
Bone is connective tissue that continuously undergoes remodeling through the precise and localized coupling of 
resorption (removal of aged material) with replacement by newly formed bone. This process (bone homeostasis) 
requires regulated interactions between different cell types such as osteoblasts, osteoclasts (large plurinucleate 
cells), bone marrow macrophages and osteocytes. The failure of this system may help explain osteoporotic frac-
tures in post-menopausal women and the elderly, a problem that has been increasing.
Osteoclast differentiation is triggered by cell-cell contact between osteoclast-precursor cells and other osteo-
genic progenitor cells in the bone including osteoblasts, osteocytes and bone marrow stromal cells1. The receptor 
activator of nuclear factor-kB ligands (RANKL) has been identified as the membrane-bound osteoclast differ-
entiation factor of osteoclastogenesis-supporting cells that form stromal osteoclasts. Osteoblasts are believed to 
be the major cell type that expresses RANKL2. Nakashima et al.3 on the other hand stated that osteocytes have a 
greater capacity to support osteoclastogenesis in vitro than osteoblasts and bone marrow stromal cells. However, 
the major source of osteoclastogenesis remains unclear, as RANKL is expressed by several cell types in bone and 
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bone marrow, including osteoblasts, osteocytes, mouse bone marrow mesenchymal stem cells (MMSC-bm) and 
lymphocytes. Therefore, it is important to know the actual cellular mechanisms of osteoclast formation to support 
work on bone remodeling.
Bone strength depends not only on the quantity of bone tissue but also on the quality, which is character-
ized by the geometry and the shape of bones, its mineral content and composition, and the fibrillar collagen 
microstructure4. Collagen is a potential candidate for bone tissue engineering and may provide innate biological 
guidance to cells that favor cell attachment and promote chemotactic responses. As an extracellular matrix pro-
tein, collagen plays an important role in bone strength and remodeling. During bone homeostasis, osteoblast 
cells undergo mineralization mainly within the bone collagen to form mature bone cells (osteocytes). It was 
reported that administration of porcine skin collagen hydrolysates enhanced bone growth5. In addition, oral 
administration of hydrolyzed type I collagen with calcitonin might inhibit bone resorption better than calcitonin 
alone6. Guillermin et al.7 reported that specific collagen amino acid sequences such as Asp-Gly-Glu-Ala, Ala, 
Hyp-, Gly-Pro-Val and Gly-Pro-Hyp are involved in bone metabolism and bone growth. Unlike type I collagen, 
the osteogenic mechanism of type II collagen (CII) has not been fully evaluated. Our previous study claimed 
the excellent biocompatible properties of shark type II collagen8. However, the influence of different molecular 
weight of type II collagens from shark cartilage with respect to the paracrine signaling mechanism of osteocytes 
for bone marrow macrophages derived osteoclast formation is needed to better understand for bone homeostasis 
and remodeling.
Results and Discussion
Effect of collagen on osteocytes. The result of proliferation assay is given in Fig. 1. On day 4, type II 
collagen (CII) and 57 kDa type II collagen polypeptide (57 kDa) treated groups (50 μg/ml) had a greater number 
of osteocytes than control, however, there were no significant differences observed between treated and control 
group on day 7. Similarly, rat tail type I collagen (150 μg/ml) coated osteocyte-like cell lines (MLO-Y4 cells) found 
to be an effective way to maintain the growth of osteocyte-like phenotype9. In another study, primary osteocytes 
culture condition was optimized using type I collagen matrix with 0.2% FBS10.
In general, osteocytes would not produce a high level of ALP, therefore, as an exploratory study, we estimated 
ALP activity to understand the regulatory mechanism of collagen and polypeptides in osteocytes. The results 
showed that the ALP level was elevated more in CII (50 μg/ml), 40 kDa type II collagen polypeptide (40 kDa) 
(1 μg/ml) and 57 kDa polypeptide treated groups than control on day 7 (p < 0.05) (Fig. 1). On day 4, there were 
no changes on ALP level in the treated groups. ALP activity is considered as an important factor in determining 
bone cell differentiation and mineralization and is used as a biochemical marker for determining mature bone cell 
phenotype. Therefore, an increased level of ALP in osteogenic cells would indicate increased osteocytes activity. 
As shown in Fig. 1, ALP activity was elevated with increasing concentrations of collagen and its polypeptides 
from 1 to 50 μg/ml compared to control. Similar to the present findings, ALP activity of murine osteoblasts was 
Figure 1. Proliferation effect (A) and ALP level (B) of pOC cells upon collagen and its polypeptides treatment. 
CII- type II collagen, 57 K and 40 K–57 and 40 kDa molecular weight collagen polypeptide, respectively. Data 
are from experiment repeated thrice with similar results. The values are mean + SEM (n = 3). *P < 0.05, vs. 
control.
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significantly increased in the presence of 1 mg/mL porcine collagen hydrolysates7. Collectively, the above findings 
support an osteogenic capability of type-II collagens and also osteocytes might secrete ALP in some extent.
mRNA expression. mRNA levels of genes of interest in osteocytes treated with collagen and polypeptides 
are shown in Fig. 2. Col2a1 mRNA levels were not significantly altered by either collagen or polypeptides treat-
ment, except high dose (50 μg/ml) of polypeptides at 1 h treatment (p < 0.05) and, low dose of CII (1 μg/ml) 
and 57 kDa (1 and 10 μg/ml) had increased the level of Col2a1 mRNA at 6 h. Il6ra mRNA levels were increased 
between 1 h and 6 h in untreated wells (p < 0.05). At 1 h and 6 h, Il6ra mRNA levels decreased with increasing 
CII and 57 kDa (50 μg/ml) (p < 0.05). It was proved that local stimulatory factors IL-6 and IL-6ra had predictive 
for osteoclast maturation, activation, and recruitment. Several studies demonstrated the higher level of IL-6ra 
responsible for bone loss in early post-menopause11,12.
Tumor necrosis factor receptor superfamily member 11B (Tnfrsf11b) mRNA levels were not significantly 
altered by either collagen or polypeptide treatment in 1 h. At 6 h, Tnfrsf11b mRNA levels were increased with 
increasing collagen (10 and 50 μg/ml) and 57 kDa (50 μg/ml) (p < 0.05). There was no significant difference 
in Tnfrsf11b mRNA levels between controls and collagen polypeptides (1 μg/ml and 10 μg/ml)-treated cells. 
Tnfrsf11b gene provides instruction for making a protein osteoprotegerin, which plays a vital role in bone remod-
eling and regulation of osteoclast cells. Tnfrsf11b acts as a decoy receptor for the receptor activator of nuclear 
factor kappa B ligand (RANKL), a major cytokine for osteoclastogenesis13. Therefore, higher expression of 
Tnfrsf11b mRNA level by collagen and 57 kDa should reduce the osteoclast formation through osteocytes signa-
ling mechanism.
Tumor necrosis factor ligand superfamily member 11 (Tnfsf11), also known as RANKL is a type-II membrane 
protein and has been identified to affect the immune system and control bone regeneration and remodeling. At 
1 h and 6 h, Tnfsf11 mRNA levels were decreased with increasing collagen and polypeptides (57 kDa and 40 kDa) 
concentration (50 μg/ml) (p < 0.05). There is strong evidence that osteocytes produce paracrine signals and reg-
ulate osteoclast formation through RANKL production3. The present study clearly depicted that treatment of 
collagen had obstructed the mRNA expression of RANKL in osteocytes.
Sost mRNA provides an instruction for producing a protein called sclerostin. It is produced in osteocytes and 
acts on the bone to stop bone formation. At 1 h, Sost mRNA levels were decreased with increasing collagen and 
Figure 2. Expression of osteogenesis regulatory mRNA relative to Hprt1 of osteocyte cells by real-time PCR. 
CII- type II collagen, 57 K and 40 K–57 and 40 kDa molecular weight collagen polypeptide, respectively. 1 h and 
6 h represent a different time interval. Data are from experiment repeated thrice with similar results, *P < 0.05, 
vs. control. The values are mean + SEM (n = 3). Bars with different alphabets (a, b and c) are significantly 
different (P < 0.05) among controls at the different time point (0, 1 and 6 h).
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polypeptides concentration (50 μg/ml) when compared to control cells (p < 0.05). There was no significant differ-
ence in Sost mRNA levels by collagen and polypeptides in 6 h. From the data, collagen had down-regulate bone 
formation inhibitor gene, i.e., sost mRNA expression, which further supported the proliferation effect of collagen 
and polypeptides on osteocytes (Fig. 1). The recent study reported the decreased formation of the mineralized 
matrix and an increased mRNA expression of Sost in osteocytes, indicating a reduction in bone formation via the 
NF-κB pathway14.
Alpl is the gene for the alkaline phosphatase (ALP) enzyme, which helps in the growth and development of 
bones through bone mineralization. This enzyme helps for the deposition of calcium and phosphorus in devel-
oping bones15. Alpl mRNA levels were increased significantly between 1 h and 6 h in untreated cells (p < 0.05). 
Except for CII, 57 kDa and 40 kDa (10 μg/ml)-treated cells, there was no significant difference in Alpl mRNA 
levels between controls and collagen/polypeptides-treated cells in 1 h. At 6 h, Alpl mRNA levels decreased in col-
lagen/polypeptides-treated cells (p < 0.05). Though, the proliferation rate and cellular alkaline phosphatase level 
of collagen treated osteocytes increased, the level of Alpl mRNA expression was not triggered at 6 h treatment. 
Several hypotheses could be possible for the above result because in general, osteocytes are not the major sources 
for ALP productions for bone formation. The earlier study could demonstrate that an induction of Alpl mRNA 
during the in vitro osteogenic differentiation process expected for bone forming capacity of the bone marrow 
stromal cells in vivo16.
Taken together, these findings suggest that the expression of osteogenic regulatory genes such as Col2a1 and 
Alpl, was triggered initially at 1 h and declined later at 6 h in collagens treated osteocytes; and osteoclasts regula-
tory genes, such as Il6ra, and Tnfsf11 were suppressed in collagen and polypeptides treated osteocytes that could 
predict to down-regulate osteocytes cues for osteoclast formation. It was earlier confirmed by few authors that 
certain specific amino acid residues (asparagine, glutamine, glycine, and alanine) of collagen interact with inte-
grin α2β1 on the mesenchymal stem cell membrane and can lead to up-regulate bone matrix synthesis through 
inhibition of TGF-beta signaling and activation of RUNX2 through FAK-JNK signaling7,17,18.
Effect of collagen on MMSC-bm. MMSC-bm activity contains three important phases including prolifer-
ation, matrix protein synthesis and mineralization of the bone matrix during new bone formation. The result of 
proliferation assay of MMSC-bm cells treated with different concentration of collagen and polypeptides is given 
in Fig. 3. In general, the proliferation rate of MMSC-bm cells was accelerated with increasing concentration of 
collagen and polypeptides. Notably, the rate was significantly higher on day 7 at 50 μg/ml of CII than other treat-
ments. Similarly, Hennessy et al. and Gao et al. disclosed the osteogenic stimulatory activities of type I collagen 
Figure 3. (A) Proliferation effect of collagen and its polypeptides on MMSC-bm cells. MMSC-bm cells cultured 
with collagen and polypeptides in the concentration of 1, 10 and 50 μg/ml. (B) Level of calcium deposit in 
MMSC-bm cells treated with collagen and polypeptides (50 μg/ml). Collagen treated MMSC-bm cells cultured 
with osteoblast medium containing osteoblast supplements for 21 days and stained with Alizarin red. Control 
and Negative control cells were cultured in osteoblastic medium with and without osteoblast supplements, 
respectively. CII- type II collagen, 57 K and 40 K–57 and 40 kDa molecular weight collagen polypeptide, 
respectively. Bars with different alphabets (a and b) are significantly different (P < 0.05) among CII and its 
polypeptides in their respective concentration. *P < 0.05, vs. control (MMSC-bm cells without collagen).
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peptides and rat tail type I collagen on mesenchymal stem cell19,20. In contrary, Song et al. observed decreasing 
trend of human bone marrow mesenchymal stem cells with coating and/or direct treatment of human type I 
collagen (5 μg/ml)21. Vleggeert-Lankamp et al. reported that bovine dermis type I collagen did not promote/
inhibit the proliferation of human Schwann cells22. In some studies, type I collagen was shown having the effect 
to increase cell proliferation, whereas, in some others, it did not have such effect, even decreased the proliferation 
of MSC cells. We speculated that this could be due to different molecular composition of collagens from different 
sources. Recently, Chiu et al.17 reported that the level of integrin α2β1 complex (VLA-2) expression on MSC-bm 
surface increased by type-II collagen treatment on day 4 and then gradually reduced from day 6 to a lower level 
than that of the control on day 10.
Collagens and polypeptides treated MMSC-bm cells cultured in osteogenic media were able to differentiate 
into the osteoblastogenic lineage cells. This was confirmed by the presence of mineralized nodules in collagens 
treated MMSC-bm cells after Alizarin red staining on day 21 (Fig. 3). In collagens untreated cultures smaller 
aggregates were observed. There was no nodular aggregate deposited in negative control cultures (cells cultured 
without osteoblast supplements). This was clearly demonstrating that collagens and polypeptides accelerated 
osteoblast lineage cells differentiation from MMSC-bm and nodular aggregates present in collagens treated cul-
tures were calcium deposits23. This is consistent with previous work showing that bone marrow-derived mesen-
chymal stem cells (BM-MSC) cultured on mammalian type-II collagen coated plates exhibited significant higher 
calcium deposition on day 12 and day 16, which suggests osteogenic induction properties of type-II collagen17. 
Collagen treated cultures had larger alizarin red positive aggregates and stained more intensively, indicating that 
a more extensive calcium deposition had occurred. The presence of alizarin red stain with nodular cell aggregates 
observed in collagen and polypeptides treated cultures establishes that these amorphous deposits contain calcium 
and suggests that calcium deposits are made up of MMSC-bm cells differentiated to the osteoblastic lineage. 
Numerous possible mechanisms have been proposed for stimulating MMSC-bm osteogenic differentiation24,25. 
Actual signaling mechanism of type II collagen during early osteogenic differentiation of MMSC-bm occurred 
by facilitating RUNX2 phosphorylation activation through integrin α2β1-FAK-JNK signaling axis, thus enhanced 
bone defect repair through an endochondral ossification-like process17.
Effect of collagen on osteoclast differentiation. Macrophages harvested from mouse bone marrow 
were treated with RANKL and mCSF in the presence and absence of different concentration of collagen and pol-
ypeptides to assess the effects of the collagens on osteoclastogenesis. The result shows that increasing concentra-
tion of collagen and its polypeptides reduced osteoclast numbers considerably (p < 0.01) (Fig. 4). In contrast, the 
Figure 4. Effect of collagen and polypeptides on osteoclastogenesis. Control-cells treated with mCSF and 
RANKL alone, P. control (Positive control)-cells treated with oncostatin M-mCSF-RANKL, CII- type II 
collagen-mCSF-RANKL, 57 K and 40 K–57 and 40 kDa molecular weight collagen polypeptides-mCSF-RANKL, 
respectively. *p < 0.05 vs control.
www.nature.com/scientificreports/
6SCiEnTiFiC REPORTS |  (2018) 8:5318  | DOI:10.1038/s41598-018-23532-x
murine oncostatin M (m-OSM) treated group increased osteoclast cell numbers (3+ nuclei) compared to control. 
But, the number of double nuclei osteoclast cells was decreased in m-OSM treated group than control (p < 0.01). 
The higher concentration of collagen and polypeptides treated groups had considerably decreased both dou-
ble nuclei and 3+ nuclei TRAP+ cells compared to control (p < 0.01). Similarly, Guillermin et al.7 reported that 
murine osteoclasts differentiation reduced by the treatment of porcine collagen hydrolysates (2 or 5 kDa) with 
1 mg/ml concentration, which might be due to inhibition of Transforming growth factor beta (TGF-β) through 
interaction of collagen-derived peptides (asparagine, glycine, glutamine and alanine).
The micrograph clearly depicted the lower number of osteoclast cells in the presence of higher concen-
tration (50 μg/ml) of collagen and its polypeptides (Fig. 5). Among the treatment, 1 μg of 57 kDa collagen 
polypeptide-treated group had a high number of osteoclast cells than other treatment groups. In higher mag-
nification (10×), “ghost” outlines remaining after osteoclast apoptosis cells were found in wells treated with the 
higher doses of CII but not in lower dose treatment. This observation indicated that increasing concentration of 
collagen increased apoptosis in osteoclasts.
Co-culture model. It was reported that differentiated primary osteoblasts express cytokines, RANKL and 
mCSF in presence of stimulators (IL-6, soluble IL-6 Receptor, prostaglandin E2 (PGE2), 1,25-Dihydroxy vitamin 
D3 (1,25 (OH)2D3) and oncostatin M), which bind with mouse BMM and support osteoclast differentiation24. 
In contrast, Nakashima et al.3 identified that purified osteocytes also express a much higher amount of RANKL 
and have a greater capacity to support osteoclastogenesis. Therefore, in the present study, we used a co-culture 
model with different stimulators to understand the effect of inducers such as m-OSM, IL-6, sIL-6R, 1,25 (OH)2D3 
and PGE2 on osteoclast formation. The primary co-culture of BMM with pOC was grown in presence of induc-
ers for 7 days. m-OSM significantly increased the number of single and double nuclei TRAP-positive cells, but 
few cells with more than 2 nuclei were observed. Compared to m-OSM, less number of TRAP-positive cells found 
in 1,25 (OH)2D3 and PGE2 group. In contrast, IL-6 in the presence of sIL6R supported only the production of 
TRAP-positive single and double  nuclei cells to some extent (Fig. 6). No TRAP-positive cells were observed in 
wells treated with IL-6 or sIL-6R alone; this can also be seen in the micrographs (Fig. 6).
Figure 5. Total number of TRAP+ osteoclast cells (double nuclei and three plus nuclei) between control and 
collagen treatment. OSM-oncostatin-mCSF-RANKL, M CII- type II collagen-mCSF-RANKL, 57 K and 40 K–57 
and 40 kDa molecular weight collagen polypeptides-mCSF-RANKL, respectively. Data are from experiment 
repeated thrice with similar results (*p < 0.05). The values are mean + SEM (n = 3).
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Our above study confirmed that osteocytes stimulated with m-OSM might support osteoclast differentiation 
to the point of a multinucleated cell, as previously observed with other stimuli in freshly isolated osteocytes26. 
Further, we aimed to understand whether collagen and its polypeptide might play a similar role in the presence 
and absence of inducer, OSM in the co-culture of BMM and pOC. TRAP-positive single and double nuclei cells 
were formed in the collagens-OSM treated group (Fig. 7), but it was lower than m-OSM alone treated group 
(Fig. 6), which confirmed that collagen and collagen polypeptides might suppress m-OSM-stimulation of osteo-
cytes towards osteoclast formation to some extent. In contrast, others reported no effect of hydrolyzed collagen on 
primary co-culture of osteoblast and osteoclasts growth7. The down-regulation of osteoclastogenesis by collagen 
might be justified by the higher level of Tnfrsf11b mRNA (a decoy receptor for RANKL) (Fig. 2) that coupled 
with m-OSM-triggered-RANKL and leads to inhibition of RANK-RANKL ligand binding towards osteoclast 
formation.
The level of inhibition was higher (p < 0.05) in a collagen-OSM group than polypeptides treated groups, which 
might be due to the suppressive mechanism of osteoclastogenic regulatory genes such as Il6ra and Tnfsf11 expres-
sion of pOC by collagen (Fig. 2). Thus, pOC could not secrete necessary cytokines in order to stimulate osteoclast 
formation from collagen treated BMM-pOC co-culture, though the presence of positive inducer, m-OSM.
Methods
Materials. Type II collagen from whale shark cartilage was extracted with 0.5 M acetic acid containing 1% 
pepsin (Sigma-Aldrich Co., Ltd, Shanghai, China) and purified by gel-filtration column chromatography using 
a Sephadex G-100 (Sigma-Aldrich) column (25 × 3 cm). Collagen polypeptides were obtained by enzyme (ther-
molysin from Bacillus thermoproteolyticus rokko, EC number: 3.4.24.27, Sigma-Aldrich) hydrolysis of collagen8. 
Briefly, 100 mg/mL collagen in 50 mM sodium phosphate buffer (pH 7.0) was hydrolyzed with thermolysin at 
0.1% (w/w) of the protein content, 70 °C) for 60 min and terminated with the addition of EDTA (20 mM) and two 
types of (57 and 40 kDa) collagen polypeptides were obtained using molecular weight cut-off filters (Millipore, 
Shanghai, China)8.
Effect of collagen and collagen polypeptides on MMSC-bm and osteocytes. Cell culture. Primary 
osteocytes (pOC) cells were harvested from mice27 (Sino-British Sippr/BK Lab Animal Co., Ltd, Shanghai, China) 
long bones (femora, and tibia) using 300 U/mL collagenase (Sigma-Aldrich) dissolved in α-minimal essential 
medium (α-MEM) (Gibco, Shanghai, China) and were cultured in α-MEM medium supplemented with 10% fetal 
bovine serum (Gibco) at 37 °C in a CO2 incubator (Shanghai Hengyue Medical Instruments Co., Ltd, Shanghai, 
China), respectively. Animal study protocols and procedures were approved by the Shanghai Ocean University insti-
tutional animal care and use committee (Permit Number: 13-0012). All methods were employed in accordance with 
the relevant guidelines and regulations of Scientific and Ethical Care and Use of Laboratory Animals of Shanghai 
Ocean University.
Figure 6. (A) Effect of Inducers on osteoclast differentiation by co-culture of bone marrow macrophages 
with p-osteocytes for 7 days. (B). Microscopic structure of BMM co-cultured with p-osteocytes in presence of 
inducers. OSM-oncostatin M, IL6- Interleukin 6, sIL6R- soluble interleukin 6 receptor, PGE2-prostaglandin E2, 
1,25D- 1α,25-Dihydroxyvitamin D3. (*p < 0.05; **p < 0.001 vs control). The values are mean + SEM (n = 3).
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Mouse bone marrow-mesenchymal stem cells (ZQ0465) (MMSC-bm) were purchased from the Shanghai 
Zhong Qiao Xin Zhou Biotechnology Co., Ltd, Shanghai, China and were cultured in mesenchymal stem cell 
culture medium (brand: Sciencell, Cat. No. 7501) containing 10% fetal bovine serum (FBS), (brand: Sciencell, 
Cat. No. 0025), mesenchymal stem cell growth supplement (1% MSCGS, Cat. No. 7552) and 1% penicillin/strep-
tomycin (10,000 units/ml of Penicillin and 10,000 μg/ml of Streptomycin in a saline solution) (Cat. No. 0503) at 
37 °C in a CO2 incubator.
Proliferation assay. After confluence, cells pOC and MMSC-bm at passage 5 were seeded (5 × 105 cells/well/48 
well plate) in microtiter plates (Costar, Shanghai) along with the different concentration of collagen and polypep-
tides (1, 10 and 50 μg/ml). Controls consisted of uncoated (without collagen) wells. The total number of viable 
cells was counted using an Invitrogen cell counter (Countess II Automated Cell Counter, ThermoFisher Scientific, 
Shanghai, China) at 0, 4 and 7 days after seeding.
Alkaline phosphatase (ALP) assay. pOC cells were generated as described above. At each time point, cells were 
washed twice with 1 × phosphate buffered saline (PBS), harvested with lysis buffer (10 mM Tris buffer, pH 7.4) 
and sonicated (40 w, Shanghai Kedao Ultrasonic Instrument Co, Shanghai, China) with an ice water-bath for 
30 sec to release cellular components. After a brief centrifugation (13,000 × g for 1 min at 4 °C, Universal 320 R, 
Andreas-Hettich, Buckinghamshire, Germany), the supernatant was used for the ALP assay. In brief, 25 µl per 
sample was added to 100 µl substrate (10 mM p-nitrophenyl phosphate (Sigma-Aldrich) in assay buffer (0.1 M 
Na2CO4 buffer, pH 10.0)). The reaction proceeded for 30 min at 37 °C; the reaction was terminated by addition of 
50 µl NaOH (1 M) and absorbance measured at 410 nm using a plate reader (Bio-Rad Model 550, Shanghai). ALP 
activity was determined from a standard curve using 10 mM p-nitrophenol from 4000 to 62.5 nmoles and with-
out substrate maintained as a control. The same volume of sample was used to determine protein content using 
bicinchoninic acid (BCA) as per the manufacturer’s instructions (Pierce, IL, USA). ALP activity was expressed as 
nmoles/min/mg protein determined as follows:
×
×
Alkaline Phosphatase concentration: ALP level 1,000
(nmoles/min/mg protein) PC Time
where, ALP level- Alkaline phosphatase level (nmoles/ml), PC- Protein concentration (μg/ml),Time-30 min
mRNA expression. pOC cells were seeded (250,000 cells/well) in 6 well microtiter plates (Costar) along with 
the different concentration of collagen and polypeptides (1, 10 and 50 μg/ml). Controls consisted of uncoated 
(without samples) wells. The percentage of mRNA expression (Sost, Alpl, Il6ra, Tnfsf11, Tnfrsf11b and Col2a1) was 
determined at a different time interval (0, 1 and 6 h) as follows.
Figure 7. Formation of TRAP-positive cells (A) and microscopic structure (B) of bone marrow macrophages 
(BMM) co-cultured with p-osteocytes in presence of oncostatin M (m-OSM) with or without collagens. CII- 
type II collagen, 57 K and 40 K–57 and 40 kDa molecular weight collagen polypeptides, respectively. Data are 
from experiment repeated thrice with similar results. *p < 0.05; **p < 0.001 vs collagen/polypeptide alone. The 
values are mean + SEM (n = 3).
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RNA Extractions (Trizol Method). Culture medium was removed from the cells by pipetting after an incu-
bation period and washed twice with ice-cold PBS. The cell monolayer was lysed in TRIzol (Invitrogen Life 
Technologies, Shanghai, China) (0.5 ml/well). The Trizol supernatant was passed through a 21 G needle using 
Luer-lock syringes (Zogear Industries Co.,Ltd, Shanghai, China) to shear the RNA. Phase separation was obtained 
by addition of 0.2 ml chloroform for each 1 ml of Trizol used and shaken vigorously by hand until the sample was 
opaque. Then cells were left on ice for a few min and spun at 12,000 × g for 15 min at 4 °C. The top clear phase 
containing RNA was collected and added to a fresh tube containing 0.5 ml isopropanol for RNA precipitation. 
The mixture was mixed thoroughly and centrifuged as previously. The pellet was washed with 0.5 ml 70% ethanol 
and re-centrifuged. The RNA pellet was suspended in an appropriate volume (10 μl) of RT-PCR water (Shanghai 
Biocolor BioScience & Technology Company, Shanghai, China). DNase treatment was done using a Turbo DNase 
kit (Shanghai Biocolor BioScience & Technology Company, Shanghai, China) as per the manufacturer’s instruc-
tions. After centrifuging at 1000 × g for 2 min at 4 °C, RNA was quantified at an absorbance of 260 nm using a 
Nanodrop ND-1000 spectrophotometer (ThermoFisher Scientific).
cDNA synthesis. First strand cDNA synthesis was done in a 20 μl reaction mixture containing 1.0 μg RNA, 10 μl 
FS master mix (Invitrogen, Shanghai, China), 3 μl random primer (Invitrogen), 1 μl affinity script (Invitrogen) 
and Molecular grade water to 20 μl. The reaction mixture was incubated at 42 °C for 30 min and 85 °C for 5 min, 
followed by 5 min at 90 °C to inactivate the RT in a Biometra T3000 thermocycler 48 (Biometra Gmbh, Gottingen, 
Germany).
Real-time polymerase chain reaction (RT-PCR) was done using a 96-well plate using an ABI 7500 Fast 
Real-Time PCR System (Applied Biosystems, Shanghai, China) using SYBR Green Fast qPCR RT Master Mix 
(Invitrogen, Shanghai, China). pOC regulatory primers designed using Primer-BLAST (Shanghai Biotechnology 
Co., Ltd, Shanghai, China) were listed in Table 1. The total volume of each PCR reaction was 10 μl, containing 5 μl 
SYBR Green Fast qPCR RT Master mix, 1.5 μl cDNA template sample, 0.5 μl of forward and reverse primers and 
2.5 μl water. The PCR reaction was carried out at 95 °C for 30 min, 40 cycles at 95 °C for 5 min, 60 °C for 30 min, 
one cycle of 95 °C for 1 h, 55 °C for 30 min and 95 °C for 30 min.
Osteogenic differentiation and quantification. MMSC-bm cells at passage 5 were initially seeded at a density of 
5 × 104 cells/well in microtiter 6 well plates. After 2 h, 50 μg/ml collagen or collagen polypeptides were added into 
each well. To induce osteogenesis, the cells were grown in osteoblast medium (Shanghai Zhong Qiao Xin Zhou 
Biotechnology Co., Ltd, Cat. No. 4601) with the addition of osteoblast growth supplement (ObGS) (Shanghai 
Zhong Qiao Xin Zhou Biotechnology Co., Ltd, Cat. No. 4652) composed of 100 nM dexamethasone, 10 mM 
b-glycerolphosphate, and 0.05 mM 2-phosphate-ascorbic acid for 21 days with media changes every 3 days. 
Control and negative control cells were grown in the culture medium without sample and ObGS, respectively. The 
effect of collagen on osteogenesis was confirmed by observing Ca deposition in cultured cells using the Alizarin 
red staining method28. Briefly, cells were washed with PBS and fixed in 4% paraformaldehyde for 30 min and 
stained with 1% alizarin red (Sinopharm Chemical Reagent Co., Ltd, Shanghai, China) containing 1% NH4OH.
Effect of collagens on osteoclastogenesis. Bone marrow macrophage (BMM) preparation and 
RANKL-induced osteoclastogenesis. Mouse bone marrow macrophages (BMM) from 8 wk old wild mice 
(Sino-British) were cultured in a T75 medium flask (Costar) (20 ml final volume) containing 30 ng/ml mCSF 
(R&D Industries, Minneapolis, MN, USA) in endotoxin-free RPMI-10% heat-inactivated fetal bovine serum 
(FBS) (Gibco). The cells were cultured for 3 days and non-adherent BMM precursors were collected by cen-
trifugation at 1,500 g for 4 min at 4 °C. The cells were re-suspended in αMEM medium (Gibco) and cell counts 
were adjusted to 50 × 105 BMM/ml. Then, they were seeded at 105 cells/well/0.2 ml medium in 48 well plates 
and treated with RANKL (100 ng/ml)/mCSF (30 ng/ml) (R&D Industries) (control group), mouse oncostatin 






















Table 1. List of primer sequence used in this study.
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The plates were incubated at 37 °C in a humidified atmosphere with 5% CO2 for 7 days. Cells were fixed in 4% 
formaldehyde (Sinopharm) for 3 min followed by ethanol: acetone (1:1) for 1 min. After brief air dry, the cells 
were incubated with tartrate-resistant acid phosphatase (TRAP) stain (Sigma) for 8 min29, and the number of 
double and triple plus nucleated TRAP-positive osteoclasts were counted under a light microscope (Olympus 
Inc.; Center Valley, PA, USA).
Co-culture model. BMM cultured as above were co-cultured with pOC (2 × 104 cells/ml) in the presence of 
inducers such as oncostatin-M (m-OSM, 50 ng/ml), 10 nM 1α,25-Dihydroxyvitamin D3 (1, 25 (OH)2 D3), 
100 nM prostaglandin E2, IL-6 (40 ng/ml) and soluble IL-6 receptor (100 ng/ml) (R&D Industries). BMM was 
also co-cultured with osteocytes in the presence of m-OSM (50 ng/ml) with or without collagen and polypeptides 
(50 μg/ml). From the previous results, m-OSM was selected as the potential inducer. Plates were incubated at 
37 °C in a humidified atmosphere with 5% CO2 for 7 days, with a media change at day 3. Cells were then fixed 
with 4% paraformaldehyde (Sigma-Aldrich) for 10 min on ice, single and double plus nucleated osteoclasts were 
counted after TRAP stain.
Conclusion
In summary, the in-vitro results obtained with pOC, MMSC-bm and osteoclast cells demonstrated that type-II 
collagen and its polypeptides were able to stimulate osteogenesis and supress osteoclastogenesis. The effect of 
collagen and its polypeptides in osteocytes and MMSC-bm cell growth is dose-dependent, which ultimately 
maintained the bone formation. Osteoclast numbers were reduced by the concentration of collagen and its pol-
ypeptides. Intriguingly, a higher concentration of type-II collagen and polypeptides treatment had up-regulated 
the osteoblast lineage cell differentiation from MMSC-bm and had down-regulated the BMM-derived osteoclast 
cell formation, suggesting that collagen or collagen hydrolysate could be helpful in the management of bone 
diseases like osteoporosis. There are numerous reports disclosing the chondrogenic properties of type II collagen 
for cartilage repair, but here we are reporting that not only chondrogenesis, type II collagen might also play some 
role in ossification through modulating osteocytes paracrine signals for osteoclastogenesis. Therefore, the present 
work concluded that type II collagen and collagen polypeptides isolated from shark cartilages might be conceiva-
ble novel biomaterials to modulate bone formation and resorption activity; and could be of potential curiosity as 
a nutritional supplement in the preclusion of bone loss in osteoporosis. This work also highlighted that in some 
parameters native collagen was more efficient than that observed in collagen polypeptides. However, one impor-
tant issue that needs to be addressed by further studies is the concern on the molecular interaction of collagen 
with osteocytes in order to maintain bone homeostasis.
Data Availability. The datasets generated and analyzed during the present study are available from the cor-
responding author upon reasonable request.
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